AzTrials
AzTrials

Medication AdherenceADHEREBRAZILNCT02066935

Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study

An observational study of Medication Adherence, run by Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi at 1 site in Brazil.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study are: 1. To estimate the prevalence of non-adherence to immunosuppressants, and to other treatment-related aspects (smoking cessation, alcohol consumption, physical activity, and appointment keeping), in KT recipients among different KT centres across different regions of Brazil; 2. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Medication Adherence
What is being tested?
kidney transplant patient
How many people
1,105 participants
Where
1 siteBrazil
Study dates
Sep 2015to 30 Sep 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Kidney Transplant patient

Who may be able to join

  • Being at least 18 years old
  • More than 1 year posttransplant
  • Willing to participate in the study by signing a written informed consent form.

Who cannot join

  • Retransplant

Trial locations and contacts

1 site in 1 country.

Brazil1 site
  • Fundação Instituto Mineiro de Estudos e Pesquisas em Nefrologia

    Juiz de Fora, Minas Gerais, 36036-330

Other trials in Brazil

About this study

Official title: Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil: Diagnosis and Associations - ADHERE BRAZIL Multicenter Study

The purpose of the study are: 1. To estimate the prevalence of non-adherence to immunosuppressants, and to other treatment-related aspects (smoking cessation, alcohol consumption, physical activity, and appointment keeping), in KT recipients among different KT centres across different regions of Brazil; 2. To explore multilevel factors associated to immunosuppressive adherence at the level of patient (socio-demographic, clinical), healthcare provider (patient satisfaction with the interpersonal dimension of care, trust in the transplant team, social support), healthcare organization (composition of the team, operational access, CIM transplant program practice patterns), and healthcare system and policies (perceived financial burden of the treatment regimen, insurance status, barriers to access to the immunosuppressive drugs, Brazilian region);

Read the detailed description

Kidney transplant (KTx) is considered the best therapeutic option for patients with chronic kidney disease (CKD), based not only on medical reasons, but also on socioeconomic ones1. One of most important determinants of kidney transplants survival is the adherence to immunosuppressive drugs. Adherence may be defined as a patient's behavior agreement regarding the prescribed treatment, including the extent to which a person takes medications, follows a diet and/or implements lifestyle changes as prescribed by health care providers. In the setting of transplantation, a recent consensus conference stated nonadherence (NAd) as "deviation from the prescribed medication regimen sufficient to adversely influence the regimen's intended effect". Risk factors for NAd, have been categorized by the WHO into five dimensions: socioeconomic factors, disease, treatment factors, patient condition and health care team and health system characteristics. 2 Looking at all vascularized transplant recipients, KTx patients are reported like the most non-adherent.3 In Brazil, which is currently the second country in the absolute number of TxR, there are only two studies about prevalence of NAd, lacking in representativeness of the Brazilian scenario4,5. In 2012, 5.385 TxR were performed, but have clear regional differences in that activity: localized mostly in the South and Southeast regions, and performed by big services with high transplant activity transplantation. In this context, the approach of NAd can be fundamental importance in view of their influence on the results.6 The scientific literature recommends to use more than one a method for assessing adherence of the therapeutic regimen. Each method has advantages and disadvantages, and no method is actually considered the gold standard. On the other hand, a combination of measures maximizes accuracy to diagnostic of NAd.7,8 We intent to identify the prevalence of NAd to immunosuppressives in Brazilian kidney transplant patients, by using the more appropriated methodology of triangulation. As secondary objectives we will design the differences between centers and regions of the country as well the risk factors to NAd.

SAMPLE, SETTING AND DATA COLLECTION

Sample, Setting: The sample size was defined based on data from the 2012 Brazilian Registry of Transplant (2012 RBT)6 available by the Brazilian Association of Transplantation (ABTO). The total number of patients transplanted in Brazil from 2000 to 2012 was 59,001 , and 20,504 patients have been registered to be monitored in transplant centers who contribute to that register. Using the OpenEpi stats program, the sample was calculated for studies of population frequency, considering the hypothetical 50% confidence interval of 5% and design effect ranging from 2.0 to 3.0. The obtained sample size ranged from 755 to 1130 patients.

Selection of the centers participating in the study: According to 2012 RTB, there are 123 active transplant center in Brazil, distributed by 22 states, which performed 5.385 KTxs in that year. We will arbitrarily divide the centers in two regions, according to their transplantation activity: Region 1 or high activity, including centers from South and Southeast region, and Region 2 or low / moderate activity accomplishing centers from North, Northeast and Midwest. To ensure representativeness of the characteristics of the centers we will also take in account other characteristics: transplantation activity, university or not, presence of multidisciplinary team. We arbitrarily made a pre-selection of the centers, considering the above questions, to invite to participate of the study. The number of patients per center will be set in relation to the number of patients being followed. Patients will be randomly selected in a regular office visit using routine computerized method previously defined.

Data Collection: Data will be collected in 6-12 months and directly register in the Research Electronic Data Capture (RedCap) system during a regular office visit to transplant service, by a trained professional. The RedCap is a safe internet program, created by the Vanderbilt University, designed exclusively for capture and storage of data that can be powered remotely by trained people. The Federal University of Juiz de Fora is part of the consortium of institutions authorized to use this program. It allows data to be collected, organized and stored in the same action, making the process of data analysis (http://www.project-redcap.org/).

VARIABLES AND MEASUREMENTS

The implementation phase of medication adherence (taking and timing dimensions, drug holidays and dose reduction) to immunosuppressive drugs is measured using three methods: a validated self-report (Basel Assessment of Adherence with Immunosuppressive Medication Scale - BAASIS), blood assay and collateral reports by health care workers.

Non-adherence to immunosuppressive drugs:

  1. Self-reported non adherence: It will be measured using the four-item validated self-report The Basel Assessment of Adherence Scale for Immunosuppressive (BAASIS) which was recently validated to Brazilian Portuguese by our group5.
  2. Collateral report: In addition, we will use a qualitative method of measuring adherence - the collateral report. We will ask to the nurse and to the medical assistant directly responsible for the follow-up care of the KTx recipients to score patients' adherence in one of three categories: good, fair or poor. "Good" or "fair" answers by one of the professionals classifies the patients as non-adherent.8
  3. Blood assay: Patients´ adherence will also measured checking if the trough blood levels of the immunosuppressive drugs are within the therapeutic range.9 Composite adherence score: In order to increase diagnostic accuracy, a composite adherence score will be calculate based on findings of the BAASIS, collateral report and blood assay. Overall NAd will be define as an indication of NAd by one of the three methods.7,8

The current physical activity level (till 150minutes/week of moderate exercise), smoking status (current), alcohol use [(>1 drink/day (women), >2 drinks/day (men)] , and appointment keeping (missed ≥ 1 appointment/last 5) are assessed by using investigator-developed questions based on previous transplant research.

Risk factors of NAd: All the five WHO dimensions will be evaluated: socio-economic (age - years; gender; race - self-defined, white or other; highest level of education; employment; marital status - married or not; family income - per month; patient-related (smoking and alcohol intake - yes,no or social, ability in identifying the immunosuppressants in use); condition/disease-related (time on dialysis - months, dialysis modality - peritoneal or hemodialysis or preemptive transplant, post transplant time - months, previous acute rejection - as recorded in the file, creatinine, actual chronic kidney disease(-CKD) stage, estimated by CKD-EPI study formulae), therapy/treatment-related (donor - deceased, living-related, or living-unrelated donor graft; number of prescribed medications, number of dosing times) and healthcare system/healthcare worker-related factors (city of origin-same or different from transplant´s center, distance to transplant center -in miles, private insurance - yes or no, and subjective evaluation of the health workers (physician and nurse; if satisfied or not). Data will be collected from medical files and directly by a complementary questionnaire.

STATISTICAL PROCEDURES Baseline characteristics will be described as continuous variables as mean ± standard deviation or median with range whenever will appropriate. Categorical variables were represented as frequencies. For checking the normality of the sample, the Kolmogorov-Smirnov and Shapiro-Wilk tests will be conducted. T-Test, Mann-Whitney and Chi-square or Fisher´s Tests will be use to assess association between explanatory variables and adherence status. Multivariate Logistic Regression analysis will be performed to assess the association between the variables on the outcome of adherence. Statistical analysis will be performed using SPSS software v.19.0 for Windows (EUA, Chicago). A p value <0.05 will consider significant.

Being tested
kidney transplant patient
Keywords
immunosuppression, medication nonadherence, kidney transplantation
Medical subject headings
Medication Adherence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • kidney transplant patientOther

    kidney transplanted patients for at least one year

Study groups in NCT02066935
Study groupRoleWhat they receive
kidney transplant patientKidney transplanted patients for at least one year
Receives: Other: kidney transplant patient

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. adherence to immunosuppressives

    Adherence will be defined by three methods: The BAASIS instrument, blood assay of the immunosuppressives and collateral report. A patients is classified as non-adherent if he/she is considered non-adherent by any of the methods.

    Measured: 1 day

Secondary outcomes (1)
  1. Risk factors to non-adherence

    Risk factors to non-adherence are socio-economic; patient-related; condition/disease-related; therapy/treatment-related;healthcare system/healthcare worker-related factors

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Feb 2014 (estimated)
  2. Study startSep 2015
  3. Primary completionSep 2017
  4. Study completion30 Sep 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
1,105 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02066935
Sponsor's protocol ID
ADHEREBZ-001
Acronym
ADHEREBRAZIL
Status last verified
Feb 2019
First submitted
10 Oct 2013
Last updated
15 Feb 2019
Results posted
No
Data monitoring committee
No

Publications

  • Neipp M, Jackobs S, Klempnauer J. Renal transplantation today. Langenbecks Arch Surg. 2009 Jan;394(1):1-16. doi: 10.1007/s00423-008-0335-1. Epub 2008 May 14.

    PubMed 18478256
  • Sabaté E. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization. 2003.

  • Denhaerynck K, Dobbels F, Cleemput I, Desmyttere A, Schafer-Keller P, Schaub S, De Geest S. Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review. Transpl Int. 2005 Oct;18(10):1121-33. doi: 10.1111/j.1432-2277.2005.00176.x.

    PubMed 16162098
  • Michelon TF, Piovesan F, Pozza R, Castilho C, Bittar AE, Keitel E, Santos A, Goldani JC, Garcia CD, Neumann J, Garcia VD. Noncompliance as a cause of renal graft loss. Transplant Proc. 2002 Nov;34(7):2768-70. doi: 10.1016/s0041-1345(02)03403-6. No abstract available.

    PubMed 12431602
  • Marsicano Ede O, Fernandes Nda S, Colugnati F, Grincenkov FR, Fernandes NM, De Geest S, Sanders-Pinheiro H. Transcultural adaptation and initial validation of Brazilian-Portuguese version of the Basel assessment of adherence to immunosuppressive medications scale (BAASIS) in kidney transplants. BMC Nephrol. 2013 May 21;14:108. doi: 10.1186/1471-2369-14-108.

    PubMed 23692889
  • Registro Brasileiro de Transplante 2012 [Online]. Available at: http://www.abto.com.br/profissionais.

  • Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005 Aug 4;353(5):487-97. doi: 10.1056/NEJMra050100. No abstract available.

    PubMed 16079372
  • Schafer-Keller P, Steiger J, Bock A, Denhaerynck K, De Geest S. Diagnostic accuracy of measurement methods to assess non-adherence to immunosuppressive drugs in kidney transplant recipients. Am J Transplant. 2008 Mar;8(3):616-26. doi: 10.1111/j.1600-6143.2007.02127.x.

    PubMed 18294158
  • Denhaerynck K, Burkhalter F, Schafer-Keller P, Steiger J, Bock A, De Geest S. Clinical consequences of non adherence to immunosuppressive medication in kidney transplant patients. Transpl Int. 2009 Apr;22(4):441-6. doi: 10.1111/j.1432-2277.2008.00820.x. Epub 2008 Dec 24.

    PubMed 19144090
  • Karlburger RL, de Pinho JHS, Basile Colugnati FA, Denhaerynck K, Medina JOP, Veras de Sandes-Freitas T, De Geest S, Sanders-Pinheiro H; ADHERE BRAZIL Study Team. Associated Factors to Nonadherence to Routine Appointments after Kidney Transplantation: The ADHERE Brazil Study. Clin Transplant. 2025 Oct;39(10):e70339. doi: 10.1111/ctr.70339.

    PubMed 41055605
  • Sertorio ES, Colugnati FAB, Denhaerynck K, De Smet S, Medina JOP, Reboredo MM, De Geest S, Sanders-Pinheiro H; ADHERE BRAZIL Study team. Factors Associated With Physical Inactivity of Recipients of a Kidney Transplant: Results From the ADHERE BRAZIL Multicenter Study. Phys Ther. 2024 Jul 2;104(7):pzae058. doi: 10.1093/ptj/pzae058.

    PubMed 38591795
  • Marsicano-Souza EO, Colugnati FAB, de Castro BBA, Van Keullen MDS, De Geest S, Sanders-Pinheiro H. Management strategies for implementing a multicenter cross-sectional study: lessons from the ADHERE Brazil study. Sao Paulo Med J. 2022 May-Jun;140(3):439-446. doi: 10.1590/1516-3180.2021.0492.R1.15092021.

    PubMed 35507993
  • Sanders-Pinheiro H, Colugnati FAB, Marsicano EO, De Geest S, Medina JOP; Adhere Brazil Consortium Group. Prevalence and correlates of non-adherence to immunosuppressants and to health behaviours in patients after kidney transplantation in Brazil - the ADHERE BRAZIL multicentre study: a cross-sectional study protocol. BMC Nephrol. 2018 Feb 20;19(1):41. doi: 10.1186/s12882-018-0840-6.

    PubMed 29463231

Questions about this trial

What is this clinical trial studying?

An observational study of Medication Adherence, run by Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Feb 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

adherence to immunosuppressives (time frame: 1 day). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02066935, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
ADHEREBRAZIL Clinical Trial NCT02066935 | AzTrials